294 related articles for article (PubMed ID: 17998811)
1. Histone deacetylase inhibitors for cancer therapy.
Kim TY; Bang YJ; Robertson KD
Epigenetics; 2006; 1(1):14-23. PubMed ID: 17998811
[TBL] [Abstract][Full Text] [Related]
2. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
4. A work in progress: the clinical development of histone deacetylase inhibitors.
Marsoni S; Damia G; Camboni G
Epigenetics; 2008; 3(3):164-71. PubMed ID: 18487953
[TBL] [Abstract][Full Text] [Related]
5. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
6. Focus on deacetylation for therapeutic benefit.
Shabbeer S; Carducci MA
IDrugs; 2005 Feb; 8(2):144-54. PubMed ID: 15696416
[TBL] [Abstract][Full Text] [Related]
7. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
Zagni C; Chiacchio U; Rescifina A
Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.
Garcia-Manero G; Issa JP
Cancer Invest; 2005; 23(7):635-42. PubMed ID: 16305991
[TBL] [Abstract][Full Text] [Related]
11. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
13. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
Cui Y; Cai J; Wang W; Wang S
Front Immunol; 2021; 12():690207. PubMed ID: 34149732
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: anticancer compounds.
Smith KT; Workman JL
Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
[TBL] [Abstract][Full Text] [Related]
18. Targeted histone deacetylase inhibition for cancer therapy.
Vigushin DM; Coombes RC
Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
